Research programme: bacteriophage therapeutics - AmpliPhi Biosciences

Drug Profile

Research programme: bacteriophage therapeutics - AmpliPhi Biosciences

Alternative Names: AB PA01; AmpliPhage-001; BioPhage-PR; BioPhage-SM

Latest Information Update: 08 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Biocontrol
  • Developer AmpliPhi Biosciences Corporation; Frenchay Hospital; University of Bath
  • Class Bacteriophages
  • Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Pseudomonal infections
  • Research Burn infections

Most Recent Events

  • 04 Aug 2016 AmpliPhi Biosciences Corporation has patent protection for bacteriophage-based therapeutics in the Japan and Australia
  • 04 Aug 2016 AmpliPhi Biosciences plans a phase I/II trial for Cystic fibrosis (AmpliPhi 10-K 2017; 9200841)
  • 14 Apr 2016 AmpliPhi Biosciences terminates its licence for bacteriophage therapeutics with Intrexon
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top